Grifols (GIFLF) EBIT Margin (2010 - 2025)
Grifols' (GIFLF) quarterly EBIT Margin came in at 16.52% in Q4 2025, down 1.0% on a YoY basis from 16.69% in Q4 2024, and little changed quarter-over-quarter from 16.53% in Q4 2024.
Powered by 
Analysis
Grifols (GIFLF) EBIT Margin (2010 - 2025) Analysis & Trends
Grifols (GIFLF) has reported EBIT Margin for 14 consecutive years, with 16.52% the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, EBIT Margin fell 1.0% year-over-year to 16.52%; the trailing twelve-month figure through Dec 2025 stood at 17.72% (up 304.0% YoY), and the FY2025 full-year result was 16.52%, down 60144.0% from the prior year.
- EBIT Margin held at 16.52% in Q4 2025 per GIFLF's latest filing, from 16.53% in the prior quarter.
- Across five years, EBIT Margin topped out at 16.53% in Q4 2024 and bottomed at 301.09% in Q4 2021.
- Historically, EBIT Margin has averaged 89.35% across 3 years, with a median of 16.52% in 2025.
- The sharpest annual moves came in 2021 and 2025: EBIT Margin jumped 6045 bps in 2021, then dropped 1 bps in 2025.
- Over 3 years, EBIT Margin stood at 301.09% in 2021, then soared by 105 bps to 16.53% in 2024, then dropped by 0 bps to 16.52% in 2025.
- According to Business Quant data, EBIT Margin over the past three periods registered 16.52%, 16.53%, and 301.09% for Q4 2025, Q4 2024, and Q4 2021 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | -25,380.93% |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 16.52% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 16.52% |
| Dec 31, 2024 | 16.53% |
| Dec 31, 2021 | -301.09% |
| Dec 31, 2020 | -361.54% |
| Mar 31, 2020 | 70.34% |
| Dec 31, 2019 | 70.36% |
| Mar 31, 2019 | 71.32% |
| Dec 31, 2018 | 6.77% |
| Jun 30, 2018 | 23.85% |
| Mar 31, 2018 | 23.91% |
| Dec 31, 2017 | 24.69% |
| Jun 30, 2017 | 25.22% |
| Mar 31, 2017 | 23.80% |
| Dec 31, 2016 | 23.20% |
| Sep 30, 2016 | 23.95% |
| Jun 30, 2016 | 22.94% |
| Mar 31, 2016 | 24.14% |
| Dec 31, 2015 | 67.56% |
| Sep 30, 2015 | 25.47% |
| Jun 30, 2015 | 23.62% |